ArticleBMC neurology2022
Serum NFL discriminates Parkinson disease from essential tremor and reflect motor and cognition severity.
Article in BMC neurology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 3 syntheses or guidelines pooled it, 35 citations in OpenAlex.
- Elevated neurofilament light chain (NfL) in blood and CSF as a biomarker for Parkinson's disease cognitive impairment: A meta-analysis.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2026Pooled it
- Potential protein blood-based biomarkers for cognitive dysfunction in Parkinson's disease: a systematic review and network meta-analysis.Frontiers in aging neuroscience · 2026Pooled it
- Cerebrospinal fluid and blood neurofilament light chain in Parkinson's disease and atypical parkinsonian syndromes: a systematic review and Bayesian network meta-analysis.Journal of neurology · 2025Pooled it
- Blood-Derived Inflammatory Indices Across Essential Tremor, Parkinson's Disease, and Progressive Supranuclear Palsy: An Exploratory Retrospective Analysis.Diseases (Basel, Switzerland) · 2026Article
- Longitudinal dynamics of serum neurofilament light chain and prognostic value for functional outcome after acute stroke: a prospective cohort study.Frontiers in neurology · 2026Article
- Neurofilament Light Chain from Neuronally Derived Extracellular Vesicles in Differentiating Parkinson's Disease from Essential Tremor with Resting Tremor.Molecular neurobiology · 2025Article
- Plasma Neurofilament Light Chain and TNF-α Correlate with Motor Features in Isolated REM Sleep Behavior Disorder.Movement disorders clinical practice · 2025Article
- Serum glial fibrillary acidic protein is elevated in early-stage late-onset essential tremor and associated with tremor progression.Journal of neural transmission (Vienna, Austria : 1996) · 2025Observational
- Nonmotor Symptoms Differ Between Essential Tremor and Tremor-Dominant Parkinson's Disease.Brain and behavior · 2025Article
- Differences in Blood and Cerebrospinal Fluid Between Parkinson's Disease and Related Diseases.Cellular and molecular neurobiology · 2024Review
- Serum Neurofilament Light-Chain Concentrations in Essential Tremor: a Case-Control Study.Cerebellum (London, England) · 2024Article
- Plasma proteomic profiles of UK Biobank participants with multiple sclerosis.Annals of clinical and translational neurology · 2024Article
- Elevated serum neurofilament light chain protein in patients with essential tremor.European journal of neurology · 2024Article
- Evaluation of ATNNeurology · 2024Article
- Serum Neurofilament Light-Chain Levels in Essential Tremor: A Replication Study.Neuro-degenerative diseases · 2024Article
- Neurofilament light chain as a mediator between LRRK2 mutation and dementia in Parkinson's disease.NPJ Parkinson's disease · 2023Article
- Brain-Biomarker Changes in Body Fluids of Patients with Parkinson's Disease.International journal of molecular sciences · 2023Review
- Neurofilament-light chain quantification by Simoa and Ella in plasma from patients with dementia: a comparative study.Scientific reports · 2023Article
- Chaudhuri's Dashboard of Vitals in Parkinson's syndrome: an unmet need underpinned by real life clinical tests.Frontiers in neurology · 2023Review
- Outcome Measures for Disease-Modifying Trials in Parkinson's Disease: Consensus Paper by the EJS ACT-PD Multi-Arm Multi-Stage Trial Initiative.Journal of Parkinson's disease · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo investigate the diagnostic value of serum neurofilament light chain (NFL) for discriminating Parkinson disease (PD) from Essential tremor (ET) and healthy controls, and to evaluate its correlation with some clinical features of PD patients.
methodsThis cross-sectional study measured NFL levels with electrochemiluminescence immunoassay in serum of 146 PD patients, 82 ET patients and 60 age-matched healthy controls. We used multivariate regression analyses to examine whether NFL contributes to PD biomarkers. Disease severity were assessed by Unified Parkinson's Disease Rating Scale part III (UPDRS III), Hoehn & Yahr (H-Y) stage and Mini-Mental State Examination (MMSE).
resultsSerum NFL levels were significantly higher in PD than in ET and healthy controls (16.6 ± 3.5, 12.2 ± 2.4 and 11.8 ± 2.4 pg/mL, respectively, p < 0.001). In patients with PD, serum NFL were markedly increased in patients with advanced H-Y stage and patients with dementia (both p < 0.001). The correlation analysis revealed that serum NFL was positively associated with UPDRS III score (r = 0.79, p < 0.001) and H-Y stage (r = 0.86, p < 0.001), and negatively correlated with MMSE scores (r = - 0.70, p < 0.001). Further multivariate regression analyses showed that serum NFL was an independent contributor to motor symptom and cognition severity in PD patients (all p < 0.01).
conclusionsSerum NFL levels were markedly elevated may be a useful clinical biomarker for discriminating PD patients from ET and controls. Serum NFL may serve as a potential blood biomarker for motor and cognition severity of PD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.